节点文献

抗高尿酸血症药物研究进展

Research progress on anti-hyperuricemic drugs

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 刘永贵赵丽嘉崔艳丽贺星沈雪砚陈常青

【Author】 LIU Yong-gui;ZHAO Li-jia;CUI Yan-li;HE Xing;SHEN Xue-yan;CHEN Chang-qing;Centre of Pharmaceutical Information,Tianjin Institute of Pharmaceutical Research;

【机构】 天津药物研究院医药信息中心

【摘要】 痛风是一种代谢性疾病,危害严重,近年来患病率呈上升趋势。尿酸排泄减少或生成增多所致的高尿酸血症是痛风的主要病因,而高尿酸又与多种疾病密切相关。降低血尿酸水平是治疗痛风,预防痛风复发的重要措施。目前,抗高尿酸血症药物主要有3类,分别是黄嘌呤氧化酶抑制剂、尿酸盐阴离子转运蛋白1(URAT1)抑制剂和尿酸氧化酶类似物。对现有抗高尿酸血症药物的现状以及研究进展进行总结,希望对其研发提供参考。

【Abstract】 Gout is a metabolic disease, and does serious harm to human beings. In recent years, gout prevalence rate assumes upwards trend. Hyperuricemia caused by decreased uric acid excretion or increased formation of uric acid may account for gout. While high uric acid is closely related to various diseases. Therefore reducing blood uric acid level is the important measure to treat gout and prevent the recurrence of gout. So far, there are three kinds of anti-hyperuricemic drugs, including xanthine oxidase inhibitors, Urate anion exchanger 1(URAT1) inhibitors, and urate oxidase analogues. The present situation and research progress of anti-hyperuricemic drugs are reviewed in this paper, in order to provide a reference for the development of anti-hyperuricemic drugs.

  • 【文献出处】 现代药物与临床 ,Drugs & Clinic , 编辑部邮箱 ,2015年03期
  • 【分类号】R589.7
  • 【被引频次】90
  • 【下载频次】3125
节点文献中: 

本文链接的文献网络图示:

本文的引文网络